{"id":176959,"date":"2015-02-06T00:00:00","date_gmt":"2015-02-05T23:00:00","guid":{"rendered":"https:\/\/www.bcfi.be\/informations-recentes-fevrier-2015-umeclidinium-vilanterol\/"},"modified":"2026-04-02T19:11:17","modified_gmt":"2026-04-02T17:11:17","slug":"informations-recentes-fevrier-2015-umeclidinium-vilanterol","status":"publish","type":"post","link":"https:\/\/h.cbip.be\/fr\/informations-recentes-fevrier-2015-umeclidinium-vilanterol\/","title":{"rendered":"Informations r\u00e9centes f\u00e9vrier 2015: um\u00e9clidinium + vilant\u00e9rol"},"content":{"rendered":"
\n\n\n\n
\n

: m\u00e9dicament soumis \u00e0 une surveillance particuli\u00e8re et pour lequel la notification d\u2019effets ind\u00e9sirables au Centre Belge de Pharmacovigilance est encourag\u00e9e.<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u00a0<\/p>\n

Anoro<\/strong>\u00ae<\/strong>(chapitre 4.1.3.2.) est une association fixe d\u2019um\u00e9clidinium bromure<\/strong> (un nouvel anticholinergique \u00e0 longue dur\u00e9e d\u2019action) et de\u00a0vilant\u00e9rol<\/strong> (un b2<\/sub>-mim\u00e9tique \u00e0 longue dur\u00e9e d\u2019action; voir 4.1.1.) qui est propos\u00e9e en inhalation dans le traitement d’entretien de la BPCO. \u00a0L’association d’un b2<\/sub>-mim\u00e9tique \u00e0 longue dur\u00e9e d\u2019action et d’un anticholinergique \u00e0 longue dur\u00e9e d\u2019action ne se justifie que lorsqu’une de ces deux composantes n’est pas suffisamment efficace. Les effets ind\u00e9sirables sont ceux des deux composantes. Comme les autres anticholinergiques inhal\u00e9s, l\u2019um\u00e9clidinium expose \u00e0 des effets ind\u00e9sirables anticholinergiques (voir 4.1.2.), et la prudence s’impose chez les patients atteints d’une affection cardio-vasculaire instable ou d\u2019un glaucome \u00e0 angle ferm\u00e9. Il n’est pas prouv\u00e9 que l’um\u00e9clidinium et le vilant\u00e9rol apportent une plus-value par rapport aux autres bronchodilatateurs \u00e0 longue dur\u00e9e d’action.[1]<\/a><\/p>\n

De specialiteit Pre-Par<\/strong>\u00ae op basis van ritodrine, een b2<\/sub>-mimeticum dat gebruikt werd als tocolyticum, is uit de markt genomen in januari 2015.<\/p>\n

\u00a0<\/p>\n

\u00a0<\/p>\n

\n
\n
\n


[1]<\/a>Pharma Selecta <\/em>2014; 30:62-4;Australian Prescriber First published online <\/em>19 decembre 2014<\/p>\n<\/p><\/div>\n<\/p><\/div>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"

: m\u00e9dicament soumis \u00e0 une surveillance particuli\u00e8re et pour lequel […]<\/p>\n","protected":false},"author":9,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12,178],"tags":[20213,20224],"class_list":["post-176959","post","type-post","status-publish","format-standard","hentry","category-actualites","category-2015-fr","tag-import_tags","tag-import_tags-nl"],"_links":{"self":[{"href":"https:\/\/h.cbip.be\/fr\/wp-json\/wp\/v2\/posts\/176959","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/h.cbip.be\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/h.cbip.be\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/h.cbip.be\/fr\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/h.cbip.be\/fr\/wp-json\/wp\/v2\/comments?post=176959"}],"version-history":[{"count":1,"href":"https:\/\/h.cbip.be\/fr\/wp-json\/wp\/v2\/posts\/176959\/revisions"}],"predecessor-version":[{"id":179533,"href":"https:\/\/h.cbip.be\/fr\/wp-json\/wp\/v2\/posts\/176959\/revisions\/179533"}],"wp:attachment":[{"href":"https:\/\/h.cbip.be\/fr\/wp-json\/wp\/v2\/media?parent=176959"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/h.cbip.be\/fr\/wp-json\/wp\/v2\/categories?post=176959"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/h.cbip.be\/fr\/wp-json\/wp\/v2\/tags?post=176959"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}